Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics logo
$138.43 -1.10 (-0.79%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$139.35 +0.92 (+0.66%)
As of 10/23/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
1
Buy
17

Based on 18 Wall Street analysts who have issued ratings for Protagonist Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 18 analysts, 1 has given a hold rating, 15 have given a buy rating, and 2 have given a strong buy rating for PTGX.

Consensus Price Target

$158.19
14.27% Upside
According to the 18 analysts' twelve-month price targets for Protagonist Therapeutics, the average price target is $158.19. The highest price target for PTGX is $190.00, while the lowest price target for PTGX is $82.00. The average price target represents a forecasted upside of 14.27% from the current price of $138.43.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PTGX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTGX Analyst Ratings Over Time

TypeCurrent Forecast
10/25/25 to 10/25/26
1 Month Ago
9/25/25 to 9/25/26
3 Months Ago
7/27/25 to 7/27/26
1 Year Ago
10/25/24 to 10/25/25
Strong Buy
2 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
15 Buy rating(s)
16 Buy rating(s)
13 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$158.19$147.13$123.00$74.00
Forecasted Upside14.27% Upside3.72% Upside-9.27% Downside-1.15% Downside
Consensus RatingBuyModerate BuyModerate BuyModerate Buy

PTGX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PTGX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Protagonist Therapeutics Stock vs. The Competition

TypeProtagonist TherapeuticsHealthcare CompaniesBroader Market
Consensus Rating Score
3.06
2.32
2.53
Consensus RatingBuyHoldModerate Buy
Predicted Upside14.27% Upside1,400.11% Upside16.92% Upside
News Sentiment Rating
Neutral News

See Recent PTGX News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/23/2026
Weiss Ratings logo
Weiss Ratings
3 of 5 stars
 DowngradeBuy (B-) ➝ Hold (C+)
10/21/2026
TD Cowen logo
TD Cowen
3 of 5 stars
Tara Bancroft
Tara Bancroft
Not Rated
Boost TargetBuy$155.00 ➝ $160.00+14.31%
10/14/2026
Zacks Research logo
Zacks Research
4 of 5 stars
 UpgradeHold ➝ Strong-Buy
10/12/2026Initiated CoverageBuy$184.00+28.02%
10/12/2026Reiterated RatingOutperform$150.00 ➝ $190.00+32.19%
9/1/2026Boost TargetOverweight$153.00 ➝ $180.00+21.83%
9/1/2026Boost TargetOutperform$178.00 ➝ $190.00+28.60%
8/31/2026Boost TargetBuy$175.00 ➝ $182.00+24.07%
8/31/2026 Reiterated RatingOutperform
8/31/2026Boost TargetBuy$167.00 ➝ $170.00+17.59%
8/10/2026Boost TargetBuy$145.00 ➝ $170.00+15.09%
8/10/2026Boost TargetOutperform$118.00 ➝ $173.00+14.54%
8/10/2026UpgradeNeutral ➝ Buy$110.00 ➝ $186.00+27.51%
7/17/2026 Set Target$165.00+24.98%
5/6/2026Boost TargetMarket Outperform$120.00 ➝ $137.00+35.46%
3/19/2026Boost TargetOverweight$95.00 ➝ $106.00+4.07%
3/18/2026Reiterated RatingBuy$121.00+23.09%
10/28/2025Reiterated RatingBuy$82.00+8.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:42 PM ET.


PTGX Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Protagonist Therapeutics is $158.19, with a high forecast of $190.00 and a low forecast of $82.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There is currently 1 hold rating, 15 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTGX shares.

According to analysts, Protagonist Therapeutics's stock has a predicted upside of 14.27% based on their 12-month stock forecasts.

Over the previous 90 days, Protagonist Therapeutics's stock had 6 upgrades and 2 downgrades by analysts.

Protagonist Therapeutics has been rated by research analysts at Barclays, BMO Capital Markets, Citigroup, HC Wainwright, Leerink Partners, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Wedbush, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like Protagonist Therapeutics more than other "healthcare" companies. The consensus rating for Protagonist Therapeutics is Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how PTGX compares to other companies.


MarketBeat monitors more than a dozen sources for Protagonist Therapeutics analyst ratings, with the most recent rating issued on 10/23/2026.
From Our Partners